https://rss.onlinelibrary.wiley.com/doi/pdf/10.1111/j.2517-6161.1977.tb01600.x

Maximum likelihood from incomplete data via the EM algorithm

THE DESIGN AND ANALYSIS OF EXPERIMENTS. By Oscar Kempthorne. New York, John Wiley and Sons, Inc., 1952. 631 pp. $8.50. This book by a teacher of statistics (as well as a consultant for \"experimenters\") is a comprehensive study of the philosophical background for the statistical design of experiment. It is necessary to have some facility with algebraic notation and manipulation to be able to use the volume intelligently. The problems are presented from the theoretical point of view, without such practical examples as would be helpful for those not acquainted with mathematics. The mathematical justification for the techniques is given. As a somewhat advanced treatment of the design and analysis of experiments, this volume will be interesting and helpful for many who approach statistics theoretically as well as practically. With emphasis on the \"why,\" and with description given broadly, the author relates the subject matter to the general theory of statistics and to the general problem of experimental inference. MARGARET J. ROBERTSON

The Design and Analysis of Experiments

Statistics for Spatial Data.

Free radicals, metals and antioxidants in oxidative stress-induced cancer

bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P = 0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. Conclusions The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non–small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

/pdf/paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-4d5hxp2t6m.pdf

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Likelihood inference for exchangeable continuous data with covariates and varying cluster sizes; use of the Farlie–Gumbel–Morgenstern model

A note on the local asymptotically minimax rate for estimating a crossing point in a diagnostic marker problem

/pdf/sequential-designs-for-clinical-trials-2ecc05wa34.pdf

Sequential designs for clinical trials

https://projecteuclid.org/download/pdf_1/euclid.aop/1176996940

Inequalities for Multitype Branching Processes

/pdf/group-sequential-tests-with-data-dependent-treatment-2wch4nh1qc.pdf

Bruce W. Turnbull

Papers

Likelihood inference for exchangeable continuous data with covariates and varying cluster sizes; use of the Farlie–Gumbel–Morgenstern model

A note on the local asymptotically minimax rate for estimating a crossing point in a diagnostic marker problem

Sequential designs for clinical trials

Inequalities for Multitype Branching Processes

Group Sequential Tests with Data-Dependent Treatment Allocation